Farxiga approved to reduce risk for CKD progression
(HealthDay)—Farxiga (dapagliflozin) oral tablets are now approved for adults with chronic kidney disease at risk for disease progression, the U.S. Food and Drug Administration announced Friday.
- Next story Investigating the role of Brd4 in diet-induced obesity
- Previous story HPV vaccination rates suboptimal within ages 9 to 12 years
Explore more
- Biden to Withdraw Combat Troops From Afghanistan by Sept. 11
After years of arguing against an extended military presence in Afghanistan, President... - China rejects claim of illness at Wuhan lab in late 2019
China on Monday dismissed as “totally untrue” reports that three researchers in... - Samsung bets big on the Galaxy A in the U.S. with 5 phones, starting at $110
Samsung is betting big on the midrange A series in the U.S.... - Why vitamin K2 is important
Reader Kari B. from Lincoln, Nebraska writes: - New York City Can’t Just Gentrify Its Way Back to Normal
Outdoor cafes and to-go cocktails are scenes from a privileged lockdown. What... - Opiate overdoses linked to poor mental health
The opioid epidemic is taking a deadly toll on people in disproportionate... - Long delayed Rainbow Six game will make its debut at Ubisoft’s E3 conference
A deep-dive on the upcoming Rainbow Six title is also scheduled for... - Facebook will no longer remove claims Covid-19 was manmade
- Study finds heart transplantation using donation after cardiac death with NRP
A new study, presented today at the AATS 101st Annual Meeting, found... - Structural racism contributes to the racial inequities in social determinants of psychosis
The legacy of systemic racism in the U.S impacts psychosis risk at...